Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 6/20 | 1.00 |
| ▸ | GABBR1 | Q9UBS5 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10507284 | 0.78 | GABBR2 (0.64) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Hydrochloric Acid SCHEMBL10681987 | 0.76 | GABBR2 (0.62) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL9779274 | 0.75 | GABBR2 (0.61) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL7396004 | 0.75 | GABBR2 (0.61) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL7031963 | 0.73 | GABBR2 (0.74) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Arbaclofen SCHEMBL351220 | 0.73 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL19333 | 0.73 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL5556250 | 0.73 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL19334 | 0.73 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL7669749 | 0.72 | GABBR2 (0.58) | GABBR2GABBR1LMNACYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190167632-A1 | METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) | MUELLER WOLFGANG S (US) | 2019-06-06 | — | — | US | claimed |
| US-20190125779-A1 | PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2019-05-02 | — | — | US | claimed |
| US-10238622-B2 | Methods of treating and preventing/reducing the likelihood of Mesial temporal lobe epilepsy (TLE) | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2019-03-26 | — | — | US | claimed |
| US-20170042929-A9 | Methods of Treating Neurological Diseases | UNIVERSITY OF HOUSTON | 2017-02-16 | — | — | US | claimed |
| WO-2016109624-A1 | PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2016-07-07 | — | — | WO | claimed |
| US-20150051166-A1 | Methods of Treating Neurological Diseases | ZIBURKUS JOKUBAS (US) | 2015-02-19 | — | — | US | claimed |
| WO-2014028883-A1 | METHODS OF TREATING OF NEUROLOGICAL DISEASES | UNIVERSITY OF HOUSTON (US) | 2014-02-20 | — | — | WO | claimed |
| US-20120115919-A1 | METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2012-05-10 | — | — | US | claimed |
| WO-2011113904-A1 | MEDICAMENTS FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-09-22 | — | — | WO | claimed |
| US-20090252786-A1 | Use of a Biologically Active Blood Serum for the Treatment of a Disorder Characterized in a Reduced Function of a GABA Receptor | OWEN HOLDING LTD. (GB) | 2009-10-08 | — | — | US | claimed |
| US-20060089335-A1 | Compositions and methods for enhancing cognitive function and synaptic plasticity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-04-27 | — | — | US | claimed |
| EP-1644043-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA Pharma AG (DE) | 2006-04-12 | — | — | EP | claimed |
| WO-2005037215-A2 | COMPOSITIONS AND METHODS FOR ENHANCING COGNITIVE FUNCTION AND SYNAPTIC PLASTICITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-04-28 | — | — | WO | claimed |
| WO-2004105795-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA PHARMA AG (DE) | 2004-12-09 | — | — | WO | claimed |
| EP-1344524-A1 | Reflux inhibitors | AstraZeneca AB (SE) | 2003-09-17 | — | — | EP | claimed |
| EP-0936906-B1 | REFLUX INHIBITORS | ASTRAZENECA AB (SE) | 2003-09-10 | — | — | EP | claimed |
| US-20030162754-A1 | Use of GABA and GABAB agonists | TUFTS UNIVERSITY | 2003-08-28 | — | — | US | claimed |
| US-6117908-A | Use of GABAB receptor agonists as reflux inhibitors | ASTRA AKTIEBOLAG (SE) | 2000-09-12 | — | — | US | claimed |
| EP-0936906-A1 | REFLUX INHIBITORS | Astra Aktiebolag (SE) | 1999-08-25 | — | — | EP | claimed |
| WO-1998011885-A1 | REFLUX INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-03-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089335-A1 | Compositions and methods for enhancing cognitive function and synaptic plasticity | GRIN2B, CACNA1B, GRIN2A | GABBR2 63/4885GABBR1 54/4885LMNA 4077/4885 |
| US-20090252786-A1 | Use of a Biologically Active Blood Serum for the Treatment of a Disorder Characterized in a Reduced Function of a GABA Receptor | GABBR1, GABBR2, GABRA2 | GABBR2 2/4885GABBR1 1/4885LMNA 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.